International Doctoral School
Medical University of Lodz

Marta Urbaniak

"Atypical chronic lymphocytic leukemia. Analysis of immunophenotype, cytogenetics and clinics. Retrospective assessment of patients diagnosed with atypical chronic lymphocytic leukemia."

Marta Urbaniak, Tadeusz Robak, Elżbieta Iskierka - Jażdżewska
Department of Hematology, Copernicus Memorial Hospital in Lodz, Poland



Morphological features of classic (A,B) and large (C,D) CLL cells. Mature CLL cells are lymphocytes with a narrow border of cytoplasm and partially aggregated chromatin in a dense nucleus ((A)—peripheral blood, (B)—bone marrow). Large atypical CLL cells ((C)—peripheral blood, (D)—bone marrow); magnification 63.
Atypical Chronic Lymphocytic Leukemia—The Current Status. Robak T. et al. Cancers 2023.

Evaluation of:

1)The immunophenotype (especially antigens: CD5, CD43, CD200).
2)Cytogenetics (especially CLL's typical cytogenetic disorders, such as: chromosome 12 trisomy, 13q deletion, 17p deletion, 11q deletion).
3)Results of blood laboratory tests (morphology, biochemical tests: AST, ALT, urea, CRP, LDH; coagulation profile, immunoglobulins).
4)Molecular tests (mutations of genes: NOTCH1, TP53, IGHV).
5)Clinical course of atypical chronic lymphocytic leukemia (presence of typical signs and symptoms: weight loss, hyperhidrosis, fatigue, lymphadenopathy, hepatomegaly, splenomegaly, infiltration of non lymphoid organs).
6)Presence of complications typical for chronic lymphocytic leukemia (autoimmune hemolytic anemia, immune thrombocytopenia, pure red cell aplasia).
7)Response to the treatment (clinical response, blood tests results, bone marrow cytomorphology, immunophenotype, cytogenetics, molecular tests).

Lymphatic B-cell neoplasm	Antigens					
	CD19 CD20 CD22	CD23	CD5	CD10	CD11c	CD43
CLL	+	+	+	-	-/+	+
CD5- CLL	+	+	-	-	-/+	+
CD23- CLL	+	-	+	-	-/+	+
LPL	+	-	-	-	-/+	+/-
MCL	+	-	+	-/+	-	+
FL	+	-	-	+/-	-	-
SMZL	+	-	-	-	+/-	+/-
HCL	+	-	-	-	+	-
DLBCL	+	-	-/+	-/+	-	-

Atypical immunophenotype of chronic lymphocytic leukemia. Urbaniak M. et al. Acta Haematol. Pol. 2022.

Hypothesis: The course of atypical chronic lymphocytic leukemia differs from the course of typical CLL, therefore demands an individual approach to the treatment process.



Outline of the database (April 2024)